Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.

Abstract

INTRODUCTION:

Cytoreduction is sometimes an important aim of systemic anti-tumor therapies in well-differentiated pancreatic neuroendocrine tumors (PanNETs). As there is not a gold standard treatment for these tumors in this field, we conducted a literature review in order to identify objective criteria for treatment choice.

MATERIALS AND METHODS:

We critically reviewed and performed a meta-analysis of all published clinical studies of systemic therapies in patients with well-differentiated unresectable PanNETs, selecting only those articles which reported tumor shrinkage (TS) with a waterfall plot (WP). Tumor downsizing of ≥10% was considered as objective response.

RESULTS:

We selected 17 out of 2758 studies, comprising 1118 patients with tumor response reported as WP. Proliferation index, tumor burden and anti-tumor therapies were heterogeneous. Chemotherapy alone (mainly, capecitabine/temozolomide) or in combination showed the best results, with ≥10% TS ranging from 65% to 93%. Peptide receptor radionuclide therapy combined with chemotherapy (Chemo-PRRT) and sunitinib appeared promising by inducing objective response in a significant proportion of patients (93% and 60%, respectively). Time to tumor response was reported in only two trials. No clear clinical and/or biological predictive factors emerged.

CONCLUSION:

Based on response criteria used in our retrospective analysis, systemic chemotherapy alone or in combination appeared to have the main cytoreductive impact. However no conclusions regarding either a specific regimen or combination can be drawn. Furthermore, tumor population selection and/or choice of regimen may have a significant influence. Further analysis should be also conducted to identify potential predictive biomarkers of responses, in order to design future prospective interventional clinical trials enrolling more homogenous populations of advanced well-differentiated PanNETs.

• Authors: Marta Pozzari, Patrick Maisonneuve, Francesca Spada, Alfredo Berruti, Vito Amoroso, Chiara Alessandra Cella, Alice Laffi, Stefania Pellicori, Emilio Bertani, Nicola Fazio
• Journal: Cancer treatment reviews (Cancer Treat Rev) Vol. 71 Pg. 39-46 (Dec 2018) ISSN: 1532-1967 [Electronic] Netherlands
• PMID: 30352319 (Publication Type: Journal Article, Meta-Analysis, Review)
• Copyright: Copyright © 2018 Elsevier Ltd. All rights reserved.

Chemical References

• Radiopharmaceuticals
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Capecitabine
• Sunitinib
• Temozolomide

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Capecitabine (administration & dosage)
• Cytoreduction Surgical Procedures (methods)
• Humans
• Molecular Targeted Therapy (methods)
• Neuroendocrine Tumors (pathology, therapy)
• Pancreatic Neoplasms (pathology, therapy)
• Radiopharmaceuticals (therapeutic use)
• Sunitinib (therapeutic use)
• Temozolomide (administration & dosage)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)